open access
Ruxolitinib-associated squamous cell carcinoma
, 123, 123
Affiliations- Dermatology and Venereology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte EPE, Lisbon, Portugal
- Dermatology and Venereology Universitary Clinic, Faculty of Medicine, University of Lisbon, Lisbon, Portugal
- Dermatology Research Unit, iMM João Lobo Antunes, University of Lisbon, Lisbon, Portugal
open access
Abstract
Abstract
Keywords
JAK inhibitors, non-melanoma skin cancer, ruxolitinib
About this articleTitle
Ruxolitinib-associated squamous cell carcinoma
Journal
Issue
Article type
Clinical vignette
Pages
293-294
Published online
2022-07-28
Page views
3548
Article views/downloads
222
DOI
Bibliographic record
Acta Haematol Pol 2022;53(4):293-294.
Keywords
JAK inhibitors
non-melanoma skin cancer
ruxolitinib
Authors
Miguel Alpalhão
Luís Soares-Almeida
Paulo Filipe
References (10)- de Oliveira AB, Alpalhão M, Filipe P, et al. The role of Janus kinase inhibitors in the treatment of alopecia areata: a systematic review. Dermatol Ther. 2019; 32(5): e13053.
- Peterson DM, Vesely MD. Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient. JAAD Case Rep. 2020; 6(4): 257–259.
- Harris JE, Rashighi M, Nguyen N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol. 2016; 74(2): 370–371.
- Kvist-Hansen A, Hansen PR, Skov L. Systemic treatment of psoriasis with JAK inhibitors: a review. Dermatol Ther (Heidelb). 2020; 10(1): 29–42.
- Rodrigues MA, Torres T. JAK/STAT inhibitors for the treatment of atopic dermatitis. J Dermatolog Treat. 2020; 31(1): 33–40.
- Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016; 30(8): 1701–1707.
- Lin JQ, Li SQ, Li S, et al. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis. J Am Acad Dermatol. 2022; 86(2): 339–344.
- Barbui T, Ghirardi A, Masciulli A, et al. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Leukemia. 2019; 33(8): 1996–2005.
- Polverelli N, Elli EM, Abruzzese E, et al. Second primary malignancy in myelofibrosis patients treated with ruxolitinib. Br J Haematol. 2021; 193(2): 356–368.
- Curtis JR, Lee EB, Kaplan IV, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2016; 75(5): 831–841.